The Technology
Atopic skin treatments are effective on a minority of patients due to a limited repertoire of sufficiently stable active molecules, delivery of drug to the disease target, a requirement of continuous daily applications over several months, and may also cause severe side effects.The technology aimed at engineered B. subtilis bacteria strains which will bealtered to secrete an enzyme or any other desired molecule that has the targeted therapeutic orpharmaceutical value. Specifically, the development of a B.subtilis strain that can secrete functional 3α-HSD enzymes at high titters. In addition, engineered E. Coli produces an excess of the co-factor (NADPH) that DHT reduction in the scalp and inside of the roots and hair follicles. This enzyme reduces DHT, the agent testosterone derivative believed to be responsible for male pattern balding, to the inert 3α-Androstanediol derivative. Furthermore, a carrier polymer (Pluronic) was added, thus have a living formulation that is ready to be deployed and tested .
Advantages
Engineered B.subtilis will generate slow and constant release of the 3α-HSD enzymes
Expected not to have side effects
Easy and friendly use
Slow and constant release
Prolonged treatment vs the usual treatments
Direct delivery to hair follicles using specialized comb
Applications and Opportunities
New class of of baldness treatment
Could serve as a platform for other scalp skin treatment.
Business Development Contacts
